Answers are grounded in this paper and cite their sources.
Demonstrates that dapagliflozin lowers albuminuria in patients with type 2 diabetes and hypertension, suggesting potential long-term renal and cardiovascular risk reductions.
Dapagliflozin was effective in lowering albuminuria in patients with T2DM and hypertension using renin-angiotensin system blockade therapy. Reductions in albuminuria were still present after adjusting for changes in HbA1c, SBP, body weight and eGFR. Dapagliflozin-induced improvements in glycaemic control and reductions in SBP, coupled with other potentially beneficial renal effects, may lead to a reduced long-term renal and cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Heerspink et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: